CO2019008657A2 - Composición intranasal que comprende betahistina - Google Patents
Composición intranasal que comprende betahistinaInfo
- Publication number
- CO2019008657A2 CO2019008657A2 CONC2019/0008657A CO2019008657A CO2019008657A2 CO 2019008657 A2 CO2019008657 A2 CO 2019008657A2 CO 2019008657 A CO2019008657 A CO 2019008657A CO 2019008657 A2 CO2019008657 A2 CO 2019008657A2
- Authority
- CO
- Colombia
- Prior art keywords
- betahistine
- intranasal composition
- intranasal
- neurological
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453931P | 2017-02-02 | 2017-02-02 | |
| PCT/EP2018/052695 WO2018141922A1 (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019008657A2 true CO2019008657A2 (es) | 2020-01-17 |
Family
ID=61187302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0008657A CO2019008657A2 (es) | 2017-02-02 | 2019-08-09 | Composición intranasal que comprende betahistina |
Country Status (33)
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170532A1 (en) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Treatment method |
| EP4135658A1 (en) * | 2020-04-14 | 2023-02-22 | GlaxoSmithKline Consumer Healthcare Holdings (US) LLC | Nasal spray formulation with moisturizing benefits |
| CN116209454A (zh) * | 2020-04-22 | 2023-06-02 | 萨诺蒂泽研究开发公司 | 治疗上呼吸道感染的组合物和方法 |
| WO2026062705A1 (en) | 2024-09-23 | 2026-03-26 | Troikaa Pharmaceuticals Limited | Oromucosal liquid compositions of betahistine or its pharmaceutically acceptable salt(s) and processes for preparation thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397840B1 (enExample) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
| IT1229237B (it) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | Sali di (2-(piridil)etil) metilammina |
| JPH03287535A (ja) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | プラノプロフェン水溶液 |
| JP3203056B2 (ja) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | メシル酸ベタヒスチンの経皮吸収製剤用組成物および経皮吸収製剤 |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JPH10139667A (ja) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | 水性液剤 |
| CA2446904A1 (en) | 2001-05-24 | 2003-04-03 | Alexza Pharmaceuticals, Inc. | Delivery of drug esters through an inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP3555598B2 (ja) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | 積層型インダクタ |
| JP2004196676A (ja) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | 点鼻剤 |
| JP4733333B2 (ja) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | 点鼻剤又は洗鼻剤 |
| ES2258694T3 (es) | 2003-11-11 | 2006-09-01 | Mattern, Udo | Sistema de administracion de liberacion controlada de hormonas sexuales para aplicaciones nasales. |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| CA2553309A1 (en) * | 2004-04-22 | 2005-11-03 | Mor Research Applications Ltd. | Method of food intake management |
| AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | ABSORPTION ENHANCER FOR DRUG ADMINISTRATION |
| WO2007022345A2 (en) * | 2005-08-17 | 2007-02-22 | Fleming And Company, Pharmaceuticals | Vitamin b12 nasal spray and method of use |
| WO2007076140A2 (en) | 2005-12-23 | 2007-07-05 | University Of Cincinnati | Treatment methods employing histamine h3 receptor antagonists, including betahistine |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| BRPI0821647A2 (pt) * | 2007-12-21 | 2015-06-16 | Schering Plough Healthcare | Realce da fotosestabillização de oximetazolina |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| ES2419204T3 (es) * | 2008-05-27 | 2013-08-19 | The University Of Melbourne | Métodos para tratar a mamíferos con disfunciones de la trompa de Eustaquio |
| ES2589915T3 (es) * | 2008-10-08 | 2016-11-17 | Xgene Pharmaceutical Inc | Conjugados de GABA y métodos de utilización de los mismos |
| WO2016049700A1 (en) * | 2014-10-03 | 2016-04-07 | Lachesis Biosciences Pty Ltd | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
-
2018
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/da active
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/en active Active
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/lt unknown
- 2018-02-02 EA EA201991817A patent/EA201991817A1/ru unknown
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/en not_active Ceased
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 PT PT187037494T patent/PT3474850T/pt unknown
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/en active Active
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/lt unknown
- 2018-02-02 PH PH1/2019/501785A patent/PH12019501785B1/en unknown
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
- 2018-02-02 PL PL18703749T patent/PL3474850T3/pl unknown
- 2018-02-02 TW TW107103800A patent/TWI760429B/zh active
- 2018-02-02 MX MX2019008961A patent/MX381932B/es unknown
- 2018-02-02 CN CN202410176958.XA patent/CN118356397A/zh active Pending
- 2018-02-02 HU HUE20170448A patent/HUE065336T2/hu unknown
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/hu unknown
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/pl unknown
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/ko active Active
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/fi active
- 2018-02-02 CA CA3051725A patent/CA3051725A1/en active Pending
- 2018-02-02 PT PT201704483T patent/PT3698791T/pt unknown
- 2018-02-02 RS RS20200851A patent/RS60554B1/sr unknown
- 2018-02-02 ES ES20170448T patent/ES2969301T3/es active Active
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/zh active Pending
- 2018-02-02 RS RS20240022A patent/RS65099B1/sr unknown
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 SI SI201830082T patent/SI3474850T1/sl unknown
- 2018-02-02 SI SI201831043T patent/SI3698791T1/sl unknown
- 2018-02-02 JP JP2019541717A patent/JP7714323B2/ja active Active
- 2018-02-02 MA MA46778A patent/MA46778B1/fr unknown
- 2018-02-02 HR HRP20201137TT patent/HRP20201137T1/hr unknown
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/da active
- 2018-02-02 AR ARP180100254A patent/AR111699A1/es not_active Application Discontinuation
- 2018-02-02 ES ES18703749T patent/ES2807798T3/es active Active
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/hr unknown
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/ar unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/es unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/es unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/ja not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CO2021007993A2 (es) | Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina | |
| CL2016001895A1 (es) | Compuestos | |
| CR20160222U (es) | Formas solidas de acido { [ -(3- clorofenil) -3- hidroxipiridin -2-carbonil] amino} acetico, composiciones, y usos de las mismas | |
| BR112017011972A2 (pt) | derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais | |
| PE20160052A1 (es) | Composicion farmaceutica de clorhidrato de s-cetamina | |
| UY37379A (es) | Derivados de n-(piridin-2-il)piridina-sulfonamida y su uso en el tratamiento de enfermedades | |
| PE20151005A1 (es) | Composicion farmaceutica recubierta que contiene regorafenib | |
| MX2015003140A (es) | Formulaciones de enzalutamida. | |
| MX2018011785A (es) | Derivados de indolina sustituidos como inhibidores de la replicacion viral del dengue. | |
| CO6821938A2 (es) | Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1 | |
| UY37742A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CL2015002546A1 (es) | Derivados 3-fenilpropilamina sustituidos para el tratamiento de enfermedades y trastornos oftálmicos | |
| GT201600269A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CL2015002835A1 (es) | Nuevos derivados de piridina | |
| CL2016002091A1 (es) | Compuesto de triazina y su uso para fines medicinales | |
| PE20171243A1 (es) | Composicion de liberacion modificada de orlistat y acarbosa para el tratamiento de la obesidad y trastornos metabolicos relacionados | |
| CL2019002145A1 (es) | Composición farmacéutica que comprende betahistina. | |
| CL2017000845A1 (es) | Inhibidores de gingipaina de lisina | |
| CO2019011227A2 (es) | N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso | |
| DOP2016000297A (es) | Composiciones farmacéuticas útiles para tratar enfermedades infecciosas | |
| GT201700016A (es) | [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| CL2008001766A1 (es) | Forma cristalina a y b de 3-(2r-tetrahidrofuril-metil)-2-tioxantina; inhibidor de mieloperoxidasa; procesos para su preparación; formulación farmacéutica que las comprende; y uso en el tratamiento de trastornos neuroinflamatorios,trastornos ateroscleroticos cardio y cerebrovasculares, insuficiencia cardiaca, bronquitis. | |
| MX2019009909A (es) | Composiciones farmaceuticas para terapia de combinacion. | |
| MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. |